Literature DB >> 27723253

A comprehensive renal vascular access clinic results in improved patient outcomes and reduced costs.

Shannon D Thomas1,2,3, Eugenia C Ip1, Nedal Katib1, Debbie Pugh4, Andrew Lennox1,3, Zoltan Endre2,4, Elaine Tan5, Chris Ellery5, Ramon L Varcoe1,2,3.   

Abstract

BACKGROUND: Management of vascular access for haemodialysis is a leading cause of morbidity and hospitalization in patients with end-stage renal disease. We sought to evaluate the change in admission and procedural outcomes before and after the establishment of a vascular surgeon-led comprehensive renal vascular access clinic (RVAC).
METHOD: A retrospective clinical study was conducted after an RVAC was established in January 2013, with retrospective database created for the 24-month period prior to and after.
RESULTS: The number of inpatient encounters for haemodialysis vascular access care fell over identical time periods before (n = 193) and after (n = 164) the RVAC was established. This reduction was associated with a significant decrease in length of stay (from 10.71 to 3.14 days; P = 0.0056) and thrombosed access procedures (from 32 to 16; P = 0.048). The proportion of emergency procedures fell (from 54.5 to 25.4%; P = 0.002) with a trend towards less arteriovenous fistula formations in the latter group (from 75 to 49; P = 0.099). There was also a trend towards fewer procedures in the latter group (from 195 to 151; P = 0.22). A case-mix costing analysis showed an estimated reduction in mean admission cost from $25 883.15 to $9332.81 for those 2-year periods, equating to a saving of $3.46 million associated with the introduction of the clinic.
CONCLUSION: The establishment of an RVAC has led to a variety of objective performance outcome improvements, including a decrease in hospital admission, length of stay, revision and emergency surgeries, with associated cost saving. It reflects positive outcomes observed in other surgical specialties' clinics.
© 2016 Royal Australasian College of Surgeons.

Entities:  

Keywords:  arteriovenous; clinic; endovascular; fistula; graft; health cost; health service; vascular access; vascular surgery

Mesh:

Year:  2016        PMID: 27723253     DOI: 10.1111/ans.13794

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  1 in total

1.  Use of Paclitaxel Eluting Stents in Arteriovenous Fistulas: A Pilot Study.

Authors:  Krystal Dinh; Shannon D Thomas; Tae Cho; John Swinnen; Phillip Crowe; Ramon L Varcoe
Journal:  Vasc Specialist Int       Date:  2019-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.